Ivo de Vos

MD, PhD candidate at @ErasmusMC Department of Urology.

[European Urology @EUplatinum]

Spotlight: A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer by @IvodeVos , Annick Meertens et al

Watch all our Spotlights here: https://t.co/T4jVPWYuUT

#Spotlight #UroSoMe #MedTwitter

[UroToday.com @urotoday]

Check out this detailed 21-year follow-up on the impact of PSA-based screening on #ProstateCancer morbidity and mortality from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer #ERSPC > https://t.co/6rFSppZOra @IvodeVos @MoniqueRoobol

[UroToday.com @urotoday]

Check out this detailed 21-year follow-up on the impact of PSA-based screening on #ProstateCancer morbidity and mortality from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer #ERSPC > https://t.co/6rFSppZOra @IvodeVos @MoniqueRoobol

[Roderick van den Bergh @roodvdb]

🎯After 21 yrs in Rotterdam PCa screening study: Invite 246, diagnose 14 to prevent 1 death. Invite 121, diagnose 7 to prevent 1 metastatic case. Overdiagnosis now strongly reduced (risk stratification, MRI etc). Let's bring this advantage to all men who may benefit! @uroweb

[NEJM @NEJM]

Presented at #EAU23: In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival (ProtecT trial) https://t.co/G2ABkMkyJg

#oncology

[European Urology Open Science @EurUrolOpen]

Current Issue: Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the EAU Guidelines Using Long-term Data from the EU Randomised Study of Screening for PCa Rotterdam

https://t.co/SsYsmam3C0

@IvodeVos @SRemmers92 @MoniqueRoobol

[Ivo de Vos @IvodeVos]

DAD, YOU ROCK!